Nanovibronix, Inc. (NASDAQ:FEED) Short Interest Down 61.2% in May

Nanovibronix, Inc. (NASDAQ:FEED – Get Free Report) was the target of a large drop in short interest in May. As of May 29th, there was short interest totaling 63,342 shares, a drop of 61.2% from the May 14th total of 163,391 shares. Based on an average daily volume of 280,633 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.1% of the shares of the stock are sold short.

Nanovibronix Stock Performance

Shares of FEED traded down $0.05 during mid-day trading on Friday, hitting $0.83. 459,225 shares of the company’s stock were exchanged, compared to its average volume of 1,769,525. The company has a market capitalization of $5.05 million, a P/E ratio of -0.09 and a beta of 1.51. The company has a 50-day moving average of $1.23. Nanovibronix has a fifty-two week low of $0.72 and a fifty-two week high of $17.40.

Get Nanovibronix alerts:

Nanovibronix (NASDAQ:FEED – Get Free Report) last announced its quarterly earnings data on Monday, May 18th. The company reported ($6.88) earnings per share for the quarter. The business had revenue of $0.65 million during the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Nanovibronix in a report on Friday, April 24th. Wall Street Zen upgraded shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a report on Tuesday, April 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Nanovibronix currently has an average rating of “Sell”.

Read Our Latest Stock Analysis on FEED

About Nanovibronix

(Get Free Report)

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.

See Also

• Five stocks we like better than Nanovibronix
• 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
• What to Expect From Q2 Earnings as Tech Strength Broadens
• Viasat’s Orbiting Profits: Space Force Jackpot?
• Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters

Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.